Biological Response Modifiers in Combination with Antivirals against Experimentally-Induced Virus Infections
Biological response modifiers (BRMs) have particular promise when used in combination with more standard antiviral agents for treatment of viral diseases. Reported here are a series of studies which have used two BRMs in combination with the antiviral drug, ribavirin (l-β-o-ribofuranosyl-1,2,4-triaz...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
1992-01-01
|
| Series: | Canadian Journal of Infectious Diseases |
| Online Access: | http://dx.doi.org/10.1155/1992/506386 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550310680199168 |
|---|---|
| author | Robert W Sidwell John H Huffman Donald F Smee John Gilbert Roland K Robins Meir Kende John Huggins |
| author_facet | Robert W Sidwell John H Huffman Donald F Smee John Gilbert Roland K Robins Meir Kende John Huggins |
| author_sort | Robert W Sidwell |
| collection | DOAJ |
| description | Biological response modifiers (BRMs) have particular promise when used in combination with more standard antiviral
agents for treatment of viral diseases. Reported here are a series of studies which have used two BRMs in
combination with the antiviral drug, ribavirin (l-β-o-ribofuranosyl-1,2,4-triazole-3-carboxamide) in treatment
of experimentally-induced phlebovirus (Punta Toro virus) infections in mice. The positive BRMs
studied include bropirimine (2-amino-5-bromo-6-phenyl-4[3H]pyrimidinone) given orally at dosages of 25, 50 and 100 mg/kg/day beginning 24 h after virus inoculation. and 7-thia-8-oxoguanosine administered
intrapcritoneally at dosages of 6.3, 12.5 and 25 mg/kg/day given 24 and 31 h after virus inoculation. In each
experiment. multiple dosages of both BRM and ribavirin were selected to range from ineffective levels to,
in certain cases with ribavirin, lethally toxic levels. Ribavirin was always administered orally twice daily
for three days starting 24 h after virus inoculation. Both drug combinations were considered synergistic,
increasing the therapeutic index compared to either drug used alone, and significantly reducing the
evidence of ribavirin toxicity. Efficacy was seen as increased survivors, decreased virus recovery from tissues
and blood. and lowered glutamic oxalic and pyruvic transaminase levels in the serum. |
| format | Article |
| id | doaj-art-df2fc1d85cfb417189d9bcf763b5dd03 |
| institution | Kabale University |
| issn | 1180-2332 |
| language | English |
| publishDate | 1992-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Canadian Journal of Infectious Diseases |
| spelling | doaj-art-df2fc1d85cfb417189d9bcf763b5dd032025-02-03T06:07:14ZengWileyCanadian Journal of Infectious Diseases1180-23321992-01-013Suppl B495410.1155/1992/506386Biological Response Modifiers in Combination with Antivirals against Experimentally-Induced Virus InfectionsRobert W Sidwell0John H Huffman1Donald F Smee2John Gilbert3Roland K Robins4Meir Kende5John Huggins6Institute for Antiviral Research, Utah State University, Logan, Utah, USAInstitute for Antiviral Research, Utah State University, Logan, Utah, USAInstitute for Antiviral Research, Utah State University, Logan, Utah, USAInstitute for Antiviral Research, Utah State University, Logan, Utah, USADepartment of Pharmacology, University of California at San Diego School of Medicine, LaJolla, California, USAVirus Division, US Army Medical Research Institute for Infectious Diseases, Fort Detrick, Frederick, Maryland, USAVirus Division, US Army Medical Research Institute for Infectious Diseases, Fort Detrick, Frederick, Maryland, USABiological response modifiers (BRMs) have particular promise when used in combination with more standard antiviral agents for treatment of viral diseases. Reported here are a series of studies which have used two BRMs in combination with the antiviral drug, ribavirin (l-β-o-ribofuranosyl-1,2,4-triazole-3-carboxamide) in treatment of experimentally-induced phlebovirus (Punta Toro virus) infections in mice. The positive BRMs studied include bropirimine (2-amino-5-bromo-6-phenyl-4[3H]pyrimidinone) given orally at dosages of 25, 50 and 100 mg/kg/day beginning 24 h after virus inoculation. and 7-thia-8-oxoguanosine administered intrapcritoneally at dosages of 6.3, 12.5 and 25 mg/kg/day given 24 and 31 h after virus inoculation. In each experiment. multiple dosages of both BRM and ribavirin were selected to range from ineffective levels to, in certain cases with ribavirin, lethally toxic levels. Ribavirin was always administered orally twice daily for three days starting 24 h after virus inoculation. Both drug combinations were considered synergistic, increasing the therapeutic index compared to either drug used alone, and significantly reducing the evidence of ribavirin toxicity. Efficacy was seen as increased survivors, decreased virus recovery from tissues and blood. and lowered glutamic oxalic and pyruvic transaminase levels in the serum.http://dx.doi.org/10.1155/1992/506386 |
| spellingShingle | Robert W Sidwell John H Huffman Donald F Smee John Gilbert Roland K Robins Meir Kende John Huggins Biological Response Modifiers in Combination with Antivirals against Experimentally-Induced Virus Infections Canadian Journal of Infectious Diseases |
| title | Biological Response Modifiers in Combination with Antivirals against Experimentally-Induced Virus Infections |
| title_full | Biological Response Modifiers in Combination with Antivirals against Experimentally-Induced Virus Infections |
| title_fullStr | Biological Response Modifiers in Combination with Antivirals against Experimentally-Induced Virus Infections |
| title_full_unstemmed | Biological Response Modifiers in Combination with Antivirals against Experimentally-Induced Virus Infections |
| title_short | Biological Response Modifiers in Combination with Antivirals against Experimentally-Induced Virus Infections |
| title_sort | biological response modifiers in combination with antivirals against experimentally induced virus infections |
| url | http://dx.doi.org/10.1155/1992/506386 |
| work_keys_str_mv | AT robertwsidwell biologicalresponsemodifiersincombinationwithantiviralsagainstexperimentallyinducedvirusinfections AT johnhhuffman biologicalresponsemodifiersincombinationwithantiviralsagainstexperimentallyinducedvirusinfections AT donaldfsmee biologicalresponsemodifiersincombinationwithantiviralsagainstexperimentallyinducedvirusinfections AT johngilbert biologicalresponsemodifiersincombinationwithantiviralsagainstexperimentallyinducedvirusinfections AT rolandkrobins biologicalresponsemodifiersincombinationwithantiviralsagainstexperimentallyinducedvirusinfections AT meirkende biologicalresponsemodifiersincombinationwithantiviralsagainstexperimentallyinducedvirusinfections AT johnhuggins biologicalresponsemodifiersincombinationwithantiviralsagainstexperimentallyinducedvirusinfections |